Speakers

Speakers Line-up

Featured Speakers

Patrick Kos
VP Compliance, Roche
China
Sharon Xie
Regional Quality Compliance & QP
Reckitt Benckiser, China
David Shen
Partner
Allen & Overy
Clarissa Shen
Vice President China Compliance Officer
Sanofi, China
Titi Zhang
Director, China Governance Operations|
GlaxoSmithKline
Wong Chae Sing
Head of Regional Compliance, (APAC, MEA and LATM)
Mundipharma
Jifeng Shi
Director of Compliance and Registration Department
Fosun Pharma Group
Albert Van Maaren
Regional Compliance Officer APAC
Merck Group
Marx Zhou
Head of Compliance - Greater China
Takeda (China) Holdings Co Ltd, China
Xiangjun Kong
Head of Legal
Sanofi, China
Michael Lee
Project Director
BeiGene Biotech Company
Wong Chae Sing
Director of Compliance-Emerging Markets
Mundipharma
Michelle Gon
Partner
McDermott Will & Emery
Wilson Wan
Partner
McDermott Will & Emery
Jian Li
Medical Affairs Director, Medical Information and Compliance
AstraZeneca
Henry Yao
Head of Compliance
Roche Diagnostics
Tom Chan
Head of Legal - Greater China
Takeda, China
Ivan Wong
Head of Compliance GSK China and Hong Kong
Glaxosmithkline
Yaolin Wang
Regulatory Affairs Specialist
Shanghai Hengrui Pharmaceutical Co., Ltd
John Kivel
Head of Asia Pacific Recruitment
GlaxoSmithKline
Steven Yang
EHS/Compliance Manager
Teva Pharmaceuticals
Joyce Wong
Managing Director Asia Pacific
Polaris Solution Ltd
Maria Eugenia Quindimil
APAC Ethics and Compliance Lead
UCB
Scott Chen
Product & Solution Director
Huaxia Dun & Bradstreet China
Karsten Kloppenburg
Head of Internal Audit Hub China
Bayer
Lau Lit Fui
President and COO
CVie Therapeutics Limited, Taiwan

Helen Lin
Executive Medical Director
Amgen, China

Rebecca Dai
Head Clinical Project Management – Primary Care & Women’s Healthcare, Clinical Development Operations
Bayer Pharmaceuticals, China

Paul Kong
Director of Clinical Operations
Fibrogen, China

Xin Zhang
Senior Director, Clinical Operations
Shanghai Henlius Biotech Co Ltd, China

Wang Hao
Head of Clinical Operations
Bristol Myers Squibbs Pte Ltd, China

George Lee
Clinical Project Manager
Abbott Nutrition R&D, China

George Liu
Vice President, Early Development
Harbour Biomed, China

Jo Liu
Senior Business Operations Manager
Boehringer Ingelheim, China

Zhao Xianfeng
Head of Clinical Research
Abbott Nutrition R&D, China

Isabel Han
Executive Director, Clinical Operations
Denovo Biopharma, China

Peter Knapp
Vice President, Global Logistics and Expansion
Ancillare, LP

Fred Li Yong-Guo
Vice President, Pharmaceutical R&D
Hua Medicine (Shanghai) Limited, China

Dr Bian Zhaoxiang, Associate Vice-President, Professor of School of Chinese Medicine
Director of Clinical Division
Hong Kong Baptist University, Hong Kong

Nie Zhao Hong
Quality Manager
Sihuan Pharmaceutical Holdings Group Co. Ltd, China

Dr Wang Ji Yao
Huashan Hospital, Shanghai Fudan University,
China

Nellie Chen
Director of Clinical Operations
ASLAN Pharmaceuticals, China

Dr Cao Yu
Institute Director
Affiliated Hospital of Qingdao University, China

Dr Mao Yi Min
Director of Clinical Pharmacology
Renji Hospital, China

Laura Lin
Senior Portfolio Director, PAREXEL International, China

Zheng Zhu
Director of Clinical Operations, Covance, China

Wu Tai Xiang
Director
Chinese Clinical Trials Registry, China

James Fan
Vice President of Medical and Regulatory Affairs
Protech Pharmaservices Corporation (A+ China), China

Jun WANG
Head of Development Operations
Takeda Development Center Shanghai

Na Guo
Principal Epidemiologist
GSK Shanghai R&D, China

John L. Xu
Chief Scientific Officer
Mab-Venture Biopharm Co., Ltd, China

Dr C.S. Chen M.D., Ph.D.
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China

James Creeden
Medical Director, Roche Molecular Information – APAC
Roche, China

Jason Yang, MD, PhD.
Chief Medical Officer
CStone Pharmaceuticals, China

George Liu
Vice President, Early Development
Harbour Biomed, China

Eddy Wu
Executive Director, Medical and Scientific Affairs
Allergan, China

George Guo
GMO Country Head
Novartis Pharmaceuticals (China) Oncology, China

Joe Zhou
CEO
Walvax, China

Yao-Chang Xu
CEO
Abbisko Therapeutics Co., Ltd., China

Chenguang Li
Clinical Study Manager, Evidence Generation & Clinical Research
RB, China

Tong Guo
Head of Biostatistics, Africa/Asia
QuintilesIMS, China

Jaclyn Yuen Yeng Ong
Senior Clinical Research Coordinator
Institute of Mental Health, Singapore

Barbara E. Bierer
Faculty Co-Director, Multi-Regional Clinical Trials Center of Harvard and the Brigham and Women’s Hospital (MRCT Center), and Professor of Medicine, Harvard Medical School, United States

 

Speakers Profile

Jifeng Shi
Director of Compliance and Registration Department
Fosun Pharma Group

Dr. Jifeng Shi(Jeff)is the Senior Research Fellow and the Director of Compliance and Registration Department in Fosun Pharma Group. From 2003 to 2015, he worked as CMC reviewer and coordinator of review management respectively in CDE, CFDA. He has rich experience in reviewing drug application. Dr. Jeff is proficient in regulatory policy and good at providing solution strategy for dug registration.


Marx Zhou
Head of Compliance - Greater China
Takeda (China) Holdings Co Ltd, China

Marx Zhou graduated from Law School of Nanjing University. He got LLM degree from both Nanjing University and Goettingen University (Germany).

Marx worked for Roedl&Partner as legal counsel and practiced in the area of Foreign Direct Investment. He later on worked as compliance leader for INVISTA (Apparel Asia Pacific) and Baxter (Asia Pacific, Sr. Manager) since 2007. Marx joined Takeda in 2015 as the Compliance Head for Greater China area.

Marx has 10 years+ experience in the area of legal & compliance. He also published several academic articles during his practice in the area of legal and compliance.


Michelle Gon
Partner
McDermott Will & Emery

She is stationed at the firm’s strategic alliance office, MWE China Law Offices, in Shanghai. Her practice focuses on compliance and regulatory matters, including anti-corruption, unfair competition, anti-monopoly and anti-fraud representations.  Michelle has extensive experience in handling international transactions in a wide spectrum of practice areas across China, the USA and EU countries. With her long term, on-the-ground experience of doing business both within and outside China, she provides practical advice to clients on complex legal issues. Michelle often assumes the role of external general counsel for various clients on strategic development and compliance issues.


Wilson Wan
Partner
McDermott Will & Emery

Wilson Wan has extensive experience in the areas of general corporate issues, compliance, dispute resolution, labor and other areas. For general corporate practice, Wilson Wan advises foreign and domestic companies in a wide range of issues, including corporate registration, formation and liquidation of JVs and WFOEs, investment issues, M&A, shareholder disputes, customs (import & export) issues, contract review, transaction structure design, product liability and licensing issues, governmental relationship issue, etc.


Clarissa Shen
Vice President China Compliance Officer
Sanofi, China

Clarissa Shen is Country Compliance Head, responsible for designing an effective Compliance Program for Sanofi China to uphold Sanofi Group’s highest ethical standards.

Clarissa has extensive business management experiences in the area of credit management, supply chain management; and distributorship and agent management with world’s leading Pharmaceutical and Chemical companies. Since Jan. 2009, Clarissa has progressed her career in the compliance area for both Bristol-Myers Squib (China) and Eli Lilly Asia Inc.  She holds a Bachelor degree from Shanghai University and an MBA degree from University of Canterbury, New Zealand.


Jian Li
Medical Affairs Director, Medical Information and Compliance
AstraZeneca

Li Jian joined AstraZeneca China in 2012 and is now leading medical compliance team. The mission of medical compliance in AstraZeneca China is to prevent medical compliance breach through medical compliance strategic guidance for key programs either owned or supported by company, prospective review and sign-off of all company prepared product/therapy area related materials, optimization of local compliance governance framework by local SOP preparation and training, and participation in the establishment of AstraZeneca global medical standard.

Before joining AstraZeneca China, Li Jian has been acting as Medical Advisor, Medical Affairs Manager and Medical Manager with Abbvie, Abbott and Boehringer-Ingelheim. He also has 2-year working experience in medical advertising and PR area (Havas), focusing on medical marketing strategy preparation and healthcare digital communication. Prior to his career development in pharmaceutical industry, Li Jian has 9-year clinical practice experience in respiratory medicine at Shanghai Xin Hua Hospital.   

Li Jian graduated from Shanghai Second Medical University (Bachelor, Clinical Medicine) and Shanghai Jiao Tong University (Master, Internal Medicine)


Wu Tai Xiang
Director
Chinese Clinical Trials Registry, China

Wu Tai Xiang is a pioneer and major facilitator of clinical trial transparency concept in China. He initiated clinical trial transparency theory and govern system includes clinical trial registration, transparency in the process of the trial, with good reporting results, strengthening the research ethics review system and promoting the development of edit ethics.

The clinical trial transparency system, created and developed by the Professors Wu Taixiang and his colleague professor Li Youping, is the landmark achievement of the clinical epidemiology and evidence-based medicine in China, which shows increasing importance on promoting the standardization of the management for clinical study, thereby improving the quality of clinical studies and social trust.


Lau Lit Fui
President and COO
CVie Therapeutics Limited, Taiwan

Dr. Lit-Fui Lau, Ph.D., serves as President & Chief Operating Officer of CVie Therapeutics Limited. Dr. Lau received his Ph.D. from the University of Connecticut Health Center and was a postdoctoral fellow at the Johns Hopkins University School of Medicine. Dr. Lau has 18 years of experience in a number of areas in the drug industry, ranging from early discovery, clinical development to sales and marketing. He started his drug industry career at Pfizer Global R&D in the US and then joined the senior leadership team of the GSK R&D Center in China. Recently, Dr. Lau has been Vice President of R&D and General Manager at Lee’s Pharmaceutical Holdings Limited before joining CVie Therapeutics Limited


Rebecca Dai
Head Clinical Project Management – Primary Care & Women’s Healthcare, Clinical Development Operations
Bayer Pharmaceuticals, China

Rebecca Dai, Head Clinical Project Management – Primary Care & Women’s Healthcare, Clinical Development Operations, Bayer Pharmaceuticals, China, has over 15 years industry experiences with wide sputum of clinical operations, pharmacovigilance and clinical development. In her current responsibilities, Rebecca is heading an international team of global clinical project managers, global study managers, study lead monitors and clinical medication managers who are responsible for global phase II – IV trials in Primary Care and Women’s HealthCare Therapeutic Areas. In addition to her global responsibilities, Rebecca also plays an active role in GD Beijing leadership team to consistently built and grow Asian team’s capability to drive global projects with high quality. 

Rebecca obtained her bachelor degree in Clinical Medicine from the Capital Medical University, and then served as Clinical Research Associate at Beijing KendleWits where she was responsible for supervising clinical research projects. Rebecca started her career in Bayer since 2000, as CRA and local project manager. Between 2003 and 2005, Rebecca worked in Bayer Singapore Regional office as the Regional Clinical Program Manager and subsequently was appointed as Clinical Operations Head of Asia-Pacific, in charge of 13 Countries Site Management activities in AP. After return back to Beijing in 2006, Rebecca continuously expend her global responsibilities from Regional operation Head to global TA Head of late phase development.


Xin Zhang
Senior Director, Clinical Operations
Shanghai Henlius Biotech Co Ltd, China

Dr. Xin Zhang received his medical training at Norman Bethune University of Medical Sciences in 1984 and completed three years residency as general surgeon. He received his MS degree from University of Texas, Graduate School of Biomedical Sciences in 1996. He has more than 25 years biomedical research experience in US including more than 10 years oncology basic research; over 15 years pharmaceutical drug development experience covering early drug research; pre-clinical and clinical drug development in different therapeutic area. He has both global and China local clinical trial experience with global pharm and China local companies from early to late phase development. 


Zhao Xianfeng
Head of Clinical Research
Abbott Nutrition R&D, China

Zhao Xiangfeng has more than 20 years in nutrition and clinical researches in academic and industry roles as well as led multiple clinical and epidemiological researches in China.

He was instrumental in setting up and leading the clinical and nutrition research team for Abbott Nutrition R&D in China. He sets the vision and strategy for clinical and nutrition development in China R&D center, aligned with multiple stakeholders.

In his daily role, he leads clinical trials to generate scientific evidence-based claim innovation and marketing development. He oversees the clinical operations in order to execute and deliver clinical results in a timely manner aligned with regional and global development strategy. In addition, he leads the nutrition science-based claim innovation, monitor nutrition science development, lead nutrition formulation of product innovation, and translate nutrition science into marketing and sales.


Isabel Han
Executive Director, Clinical Operations
Denovo Biopharma, China

Isabel has nineteen years of experience in Pharmaceutical Industry in China since 1997. Before joining Denovo, Isabel was the Director, Head of Operations, Covance Clinical Development Service in China where she worked for eight years taking various important leadership positions. She was a recognized contributor to the significant growth of the company in China and works very closely with different sponsors and investigators. Before Covance, Isabel worked for several global pharmaceutical companies including Boehringer Ingelheim, Actelion, AstraZeneca, Kirin, etc. Majority of her experience was in clinical research area covering Clinical Operations and Project Management. Isabel has extensive experience in managing clinical trials in China both for global studies and China registration studies.


Dr Bian Zhaoxiang, Associate Vice-President, Professor of School of Chinese Medicine
Director of Clinical Division
Hong Kong Baptist University, Hong Kong

Prof Bian Zhaoxiang had been educated in Nanjing University of Traditional Chinese Medicine (TCM), Beijing University of TCM and Guangzhou University of TCM; and was conferred the Ph.D. degree in Integrated Chinese and Western Medicine in 1994. Currently, he is the Associate Vice-President, Professor of School of Chinese Medicine, Director of Clinical Division and Associate Director of Institute of Creativity of Hong Kong Baptist University. He is also the Honorary Professor of the Shanghai University of TCM, and the Chinese Academy of Chinese Medical Sciences, China. As an active member in the academic field, he dedicates himself on medical research with now having hundreds of academic papers published. Besides, he has been invited to be the reviewer of several grants, including the National Natural Science Foundation of China and Research Grant Council of Hong Kong. He also serves as reviewer or editorial board member for many international journals.

Research Interests
Prof Bian's research focuses mainly on the relationship between psychological stress and digestive diseases, especially focusing on colorectal cancer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Major research topics include: 1) basic mechanism of stress-related diseases, such as gastrointestinal disorder, depression and cancer; 2) pharmacological effect of Chinese medicine formulas and their active compounds for chronic diseases, mainly for cancer and inflammation; 3) clinical trial with Chinese medicine for digestive diseases, including colorectal cancer, IBS, IBD and functional constipation; 4) new drug development based on Chinese herbal medicine and its active fraction for digestive diseases. Related studies are supported by over 30 grants, including Research Grant Council of Hong Kong and Food and Health Bureau of Hong Kong.


Nellie Chen
Director of Clinical Operations
ASLAN Pharmaceuticals, China

Nellie Chen is Director of Clinical operation, China at ASLAN Pharmaceuticals with experience working for both CRO and sponsor companies, in both device and pharma industries.

Started out in Apex Shanghai as a Clinical Research Associate to help write CSR, in-house data management, she later worked for Novartis and Bristol Myers Squibb as a Clinical Research Associate, Clinical Advisor, Clinical Site Manager and Protocol Manager with increasing and wider scope of responsibilities over the years.

Nellie has spent four years working and living in Singapore for Bristol Myers Squibb and later PAREXEL. In 2013, upon moving back to Shanghai, Nellie joined the Covidien China R&D Center (now Medtronic) as Clinical Affairs Manager and was responsible for the registration of the R&D center’s devices in the EU, US and China markets. She has been with ASLAN Pharmaceuticals since May 2016 and is responsible for the overall clinical operations in China.

Passionate about clinical operations excellence through continuous learning and innovation, Nellie graduated with a MBBS from China Medical University and Master’s in Human Genetics from Fudan University.


Nie Zhao Hong
Quality Manager
Sihuan Pharmaceutical Holdings Group Co. Ltd, China

Nie Zhaohong, Ph.D of Tianjin TCM university. 131 talents plan of SASAC of Tianjin. Quality manager of Beijing Sihuan pharmaceutical., Co, Ltd. The main filed concerned with project management and quality control of clinical trials with several TCM, chemical and biological agents from phase I to IV.

Publication

  • 以阳性药及安慰剂为对照评价五灵颗粒治疗抽动障碍肝亢风动痰火内扰证有效性和安全性的60例临床观察。2010年中国药学大会暨第十届中国药师周大会论文集 
  • 中医药国际临床研究的探索与展望.中国临床药理学杂志. 2009,(5)
  • 人参次苷H滴丸Ⅰ期人体耐受性试验研究.中国临床药理学杂志. 2012,9.
  • The Safety and Tolerance of Herbal Anti-angina Drug Compound Danshen Droplet Pill in Healthy Volunteers. Pharmacology & Pharmacy. 2015
  • 以阳性药及安慰剂为对照评价五灵颗粒治疗抽动障碍肝亢风动痰火内扰证有效性和安全性的 60 例临床观察. 中国药学大会会议论文集 2010
  • A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. Journal of Child Psychology and Psychiatry. 2015.07
  • 人参皂苷对神经递质的作用研究进展.医药前沿,待发表.
  • 溃结康治疗三硝基苯磺酸诱导炎症性肠病大鼠模型的疗效观察.药物评价研究. 2015,

Patent:
Patent of invention: 1 for first inventor (Patent Number: 201310259296.4)


Paul Kong
Director of Clinical Operations
Fibrogen, China

Paul Kong, Director of Clinical Operations, manages all ongoing clinical trial activities in FibroGen China, including site selection, study start-up, vendor management, budgeting and planning and clinical team managment since Nov 2013.

Prior to Joining Fibrogen, Paul assumed the Global Study Manager role in Roche China, where he oversaw the global studies. Paul has set up clinical development teams in mainland China, Korea, Taiwan and Hong Kong between 2008 - 2013 and oversaw all of the studies where he served as Director, Clinical Operation at Fountain Medical Development.


Peter Knapp
Vice President, Global Logistics and Expansion
Ancillare, LP

Peter Knapp is the Vice President of Global Logistics and Expansion at Ancillare, LP.  Peter oversees the entire global clinical trial supply chain for more than 500 studies in over 100 countries for Ancillare, LP. 

Peter is an experienced executive in global end-to-end supply chain management and has worked in all aspects of the supply chain from raw materials to disposal and destruction.  Prior to Ancillare, Peter held supply chain executive leadership roles in the USA, Asia, Latin America and Europe for DHL, XPO Logistics, APL Logistics and The Linde Group.  Peter’s “on the ground” experiences in all continents of the world have been instrumental in his leadership of global expansion efforts at Ancillare. He has successfully identified and launched Ancillare depots in more than 15 regions throughout the world including Latin America, Russia/Ukraine, China and Japan.

Peter holds a Bachelor degree in Global Logistics and Forwarding from Deutsche Verkehrsschule in Breman, Germany.


Wang Hao
Head of Clinical Operations
Bristol Myers Squibbs Pte Ltd, China

Hao is the Head of Regional Clinical Operations in BMS China.

Before joined BMS, Hao was the Head of Clinical Trial Process and Quality in Pfizer China R&D for 6 years, responsible for clinical trial GCP compliance through clinical processes design, technical training, and quality and risk management. When she was in Pfizer, Hao used to be the interim Head of Pfizer Wuhan R&D for 10 months, managing all functions of Pfizer Wuhan R&D and facilitated global and China R&D functional line management for Pfizer Wuhan R&D.

Hao has over 19 years of success in pharmaceutical mainly in clinical operations, quality management and training. Before Bristol-Myer Squibb and Pfizer, she was responsible for clinical trial operations in Oncology field in Eli Lilly China.

Hao holds Master degree in Clinical Medicine, major in Inflammatory Bowel Diseases.


George Lee
Clinical Project Manager
Abbott Nutrition R&D, China

George possess 10 years of clinical experience as a Clinical Manager and CRA in Pharmaceutical industry. He is also a reviewer in CFDA.

With 5 years’ experience as Clinical Manager, George conducts clinical trial in Phase I - Phase IV pharmaceutical product, having experienced the full project life cycle from project initiation (study design) through protocol development to closeout (CSR submission) in multiple countries.


Helen Lin
Executive Medical Director
Amgen, China

Helen Lin leads Amgen China Medical. She is responsible for bringing meaningful Amgen products to China Markets and collaborate with R&D centre for delivering candidates and ‘proof of concepts’ for unique unmet medical needs in China; strengthen Drug development & launch excellent capabilities; enable & accelerate R&D partnerships in China

  • Since Sept 2009, heading the Clinical development and Medical Affairs Team in AZ China
  • Since June 2008,  heading the Clinical development  and Medical Affairs Team in Merck-Serono China
  • 8y wide experience in Clinical Operation and Clinical development at Bayer Schering Pharma, Ltd
  • From July 1993 to June 2000, worked as Paediatrician at the Shanghai No.1 people’s hospital
  • Has a MD and a MBA degree

George Liu
Vice President, Early Development
Harbour Biomed, China

Dr. George Liu currently is head of early development at Harbour Biomed. Before joining Harbour Biomed, he was the director of clinical pharmacology for Novartis Oncology where he was responsible for clinical pharmacology of full development of oncology products in China, and was director of dedicated project expert, drug disposition for Sanofi Asia pacific therapeutical strategical unit (AP TSU) while he was in charge of clinical PK for Sanofi in Asia Pacific.

Dr. Liu obtained his BS from Nanjing University in 1990 and Ph. D. from pharmacy school of Purdue University in 1999.  He started his professional career at Xenobiotic Laboratories and has worked for paradigm genetics, Guildford Pharmaceuticals, and GSK with increasing responsibilities on both drug discovery and development, including significant contribution to clinical development and/or regulatory approval of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.


Eddy Wu
Executive Director, Medical and Scientific Affairs
Allergan, China

Eddy WU, Ph.D., is the Executive Medical Director for Allergan China. He  joins Allergan from 2015 and bases in Shanghai.  He has over a decade of local and global industry experience. Before joining Allergan, he worked with Novartis and based in Hong Kong, Taiwan, and Switzerland Basel. He had a track record of success in roles of increasing responsibility for Asia Pacific, Middle East & African Countries (AMAC), he drove several major Clinical development programs and regional studies, in particular PMS, retrospective and head-to-head interventional studies. He also designed and developed speaker training, advisory board programs, treatment guidelines, KOL advocacy and development plans etc.  He has extensive experience on clinical development & medical affairs and was also previously head of Health Economics & Outcome Research (HEOR) for AMAC, China & Japan in Novartis.


James Fan
Vice President of Medical and Regulatory Affairs
Protech Pharmaservices Corporation (A+ China), China

Dr. James Fan, Vice President, Clinical Research and Regulatory Affairs Dept. Generon (Shanghai) Corporation Ltd.  As Senior Medical Director,  James Fan joined ICON in 2006 till July2016, having previously held the position of Medical Director in Taiwan-based CRO, Protech Pharmaservices Corporation, and American Biotech, Optimer Pharmaceuticals, Inc for 7 years.   As a medical monitor and safety physician, he has been medical monitor for more than 50 global clinical trials, his experience also includes pharmacovigilance in the drug development in FDA/EMA, Japan and Asia pacific area. He is co-author for three clinical trial books published by Elsevier contributing to the chapters of pharmacovigilance system setup, and clinical trial in China, Taiwan, and Singapore respectively. 

As a physician of Internal Medicine, he was trained in the Shanghai Medical University Hospital with 11 years of clinical practice experience, and then he was also awarded Master of Business Study by Massey University, New Zealand.


George Guo
GMO Country Head
Novartis Pharmaceuticals (China) Oncology, China

George worked in clinical research area nearly 20 years and has riched experience for global trials. He worked in big pharmaceutical company in the past years  like MSD, Pfizer, Novo Nordisk and GSK etc. Involved in Phase I to IV studies for anti-biotic, immnounlogy, respiratory, cardivasclar, urology, endocrinolgy, and oncology area. Familiar with the FDA, EMA, PMDA and CFDA’s inspection and requirement of clinical trials. Closely worked with DIA and RDPAC for industry initiative and collaborations。

Before joined in the industry, George worked in one of the Beijing Municipal Hospital as a doctor.

He majored in clinical medicine in medical university, and has MBA background.


Chenguang Li
Clinical Study Manager, Evidence Generation & Clinical Research
RB, China

Chenguang Li is regional clinical study manager of Reckitt Benckiser(RB) Healthcare UK, the world's leading consumer health and hygiene company, with brands (such as Nurofen, Strepsils, Mucinex, Dettol, Lysol, Finish and Vanish) sold in nearly 200 countries and operations in over 60 countries.

Chenguang Li brings over 8 years of clinical operation experiences in pharmaceuticals/CRO in china. He has 4 years’ experience in project management, including the Global & Local stuidies, also the CRO management. Chenguang Li is Team-work oriented.  He is very good at communication skills and managing customers’ relationship. 

Chenguang Li has graduated from University of applied science Berlin in 2006. After graduation, he worked for Quintiles, Parexel, Shire, CASI pharmaceutical before joining RB China


James Creeden
Medical Director, Roche Molecular Information – APAC
Roche, China

Dr. James Creeden is Medical Director for Roche Molecular Information in the Asia-Pacific Region, responsible for Foundation Medicine in Asia.  Formerly Medical Director for Roche China, he was responsible for medical strategy and post-registration studies for the Roche and Genentech portfolio in China.  Dr. Creeden holds a PhD in molecular toxicology from Rutgers University and an MD from Robert Wood Johnson Medical School. Before coming to Shanghai, Dr. Creeden was Chief Medical officer for Roche Professional Diagnostics, the world's leading In Vitro Diagnostics manufacturer, from 2008 to 2014.


Na Guo
Principal Epidemiologist
GSK Shanghai R&D, China

Na Guo is a Principal Epidemiologist at GSK Shanghai R&D. She received a B.S. degree in Medicine from Shandong University, Master of Public Health in Clinical Epidemiology from University of Alberta, and Ph.D. in Outcomes Research from University of British Columbia. After 2 years of Post-doctoral research in Health Economics at McMaster University, Na joined Roche Asia-Pacific Product Development in Shanghai in 2012 as an Epidemiologist and later a Real World Data Scientist.


Yao-Chang Xu
CEO
Abbisko Therapeutics Co., Ltd., China

Yao-Chang Xu is currently the founder and CEO of Abbisko Therapeutics Inc, an innovative biopharmaceutical company dedicated to discover and develop innovative medicines.

Before that, Dr. Xu was the general manager of Biomedical Research & Development Center for Hansoh Pharmaceutical Group from 2012 to March of 2016. Prior to that, Dr. Xu was at Novartis Institutes for BioMedical Research Inc. (NIBR) as executive director of Global Discovery Chemistry based in Cambridge, Massachusetts. In 2007, Dr. Xu moved to Shanghai, China, taking an assignment as head of chemistry for China Novartis Institute for Biomedical Research (CNIBR), and responsible for medicinal chemistry, the research phase of DMPK, and analytical and bio-analytical science in China. At the same time, Dr. Xu was a key player in building up the 1.2 billion US dollar Novartis Shanghai Research Center

After obtained BS degree in Nanjing University in 1982, Dr. Xu was the first group of students in chemistry selected by government for oversea higher education. Yao earned his Ph.D. in organic chemistry at the University of Chicago in 1988, and subsequently spent two years as postdoctoral fellow at University of Sherbrooke in Canada.  After worked in cancer research as a senior scientist at BioChem Pharma Inc. for about 3 years, Dr. Xu joined Lilly in 1993 as a Senior Research scientist. At Lilly, he made important contributions to many drug research programs including clinical drug candidates for smoking cessation, depression, migraine, obesity and etc. Dr. Xu was promoted to Principal Scientist in 1997, Research Advisor in 2000, and then Head of Discovery Chemistry Research for Lead Validation in 2001, and then Head for Lead Optimization in 2003..

Dr. Xu was also intimately involved in Lilly external research activities, and was a key member of Lilly management team in building the chemistry research center in China. He spent time in China in 2003 and created the first China outsourcing organization, namely as Lilly / ChemExplorer. This setup has provided an unique staffing strategy for Lilly’s drug discovery research. He acted as CSO for the collaboration during 2004-2005 in Shanghai.


Barbara E. Bierer
Faculty Co-Director, Multi-Regional Clinical Trials Center of Harvard and the Brigham and Women’s Hospital (MRCT Center)and Professor of Medicine, Harvard Medical School, United States

Barbara E. Bierer, MD is Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital (BWH), Boston and a hematologist/oncologist. She is the faculty co-director of the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve standards for the planning and conduct of international clinical trials, with a particular focus in the emerging economies. In addition, she is the Director of the Regulatory Foundations, Ethics, and the Law program at the Harvard Catalyst, the Harvard Clinical and Translational Science Award, working across the academic spectrum to enable the clinical trial enterprise from study planning through recruitment to data acquisition and dissemination.  Previously she served as senior vice president, research at the Brigham and Women’s Hospital for over a decade, and as chair of the Secretary’s Advisory Committee on Human Research Protections, HHS.


John L. Xu
Chief Scientific Officer
Mab-Venture Biopharm Co., Ltd, China

Dr. John Xu is currently the CSO at Mab-Venture Biopharm Co., Ltd., in charge of biologics drug R&D in the oncology, autoimmunity, and cardiovascular and metabolic disease areas, from target selection through to Proof-of-Concept clinical studies. Before joining Mab-Venture, Dr. Xu worked at Novartis as Sr. Investigator, Translational Medicine, at GSK as Associate Director, Biologics Drug Discovery, and at Shanghai Benemae Pharmaceutical Corporation as Head of R&D.

Dr. Xu has more than 26 years of international biomedical R&D experience in both academic and industry settings. At Novartis, he contributed to the development of Clinical Development Plan for a number of INDs and applied biomarker strategy to assess the PD and efficacy of these drug candidates in global trials. At Benemae, he led company-wide efforts to conduct IND-enabling studies for a GLP-1 receptor agonist, designed the protocol for a phase I, randomized, double-blind, placebo-controlled, sequential parallel group, MAD study to evaluate the safety, tolerability, pharmacokinetics and early efficacy of the drug in healthy overweight/obese subjects for chronic weight management, and received “safe-to-proceed” feedback from US FDA in July 2016. In addition, a novel mAb drug candidate for the prevention and treatment of thromboembolic disorders will be ready for dual IND/CTA filing with US FDA and CFDA in the first half of 2018.

Dr. Xu received his B.S. degree in Cell Biology from Peking University and Ph.D. degree in Biochemistry from Harvard University. He was the recipient of Damon Runyon Cancer Research Foundation Fellowship when he was a post-doctoral fellow in Immunology at Stanford Medical Center and of NIH R01 Grant when he was an Assistant Professor at the University of Illinois at Urbana-Champaign. 


Jun WANG
Head of Development Operations
Takeda Development Center Shanghai

Mr. Jun WANG serves as the associate director of clinical operations in Takeda Development Center Shanghai, manage regional clinical operations study management team located in both Beijing and Shanghai, guide and lead team work as a completely integrated members of Asia Pacific region and global development team to further contribute compound development activities for China.

Jun was trained in China and has worked in the industry for more than 15 years with extensive project management experience for both pharmaceuticals and CROs, which including 7 years project management regional experience overseas enhancement in the industry across many therapeutic areas.

Jun has the deep knowledge in compound development strategies, clinical operations management, regional regulations across most of Asia Pac countries, CRO outsourcing model management, partnership oversight and vendors category management.


George Liu
Vice President, Early Development
Harbour Biomed, China

Dr. George Liu currently is head of early development at Harbour Biomed. Before joining Harbour Biomed, he was the director of clinical pharmacology for Novartis Oncology where he was responsible for clinical pharmacology of full development of oncology products in China, and was director of dedicated project expert, drug disposition for Sanofi Asia pacific therapeutical strategical unit (AP TSU) while he was in charge of clinical PK for Sanofi in Asia Pacific.

Dr. Liu obtained his BS from Nanjing University in 1990 and Ph. D. from pharmacy school of Purdue University in 1999.  He started his professional career at Xenobiotic Laboratories and has worked for paradigm genetics, Guildford Pharmaceuticals, and GSK with increasing responsibilities on both drug discovery and development, including significant contribution to clinical development and/or regulatory approval of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.